PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma
Liu, Yuxuan; van den Berg, Anke; Veenstra, Rianne; Rutgers, Bea; Nolte, Iija; van Imhoff, Gustaaf; Visser, Lydia; Diepstra, Arjan

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0072930

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2013

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Liu, Y., van den Berg, A., Veenstra, R., Rutgers, B., Nolte, I., van Imhoff, G., Visser, L., & Diepstra, A. (2013). PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma. PLoS ONE, 8(8), Article e72930. https://doi.org/10.1371/journal.pone.0072930

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Introduction

Classical Hodgkin lymphoma (cHL) is characterized by a minority of B cell derived tumor cells, named Hodgkin Reed-Sternberg cells (HRS cells) and an abundant reactive infiltrate. Despite the loss of B cell phenotype [1], HRS cells often retain their professional antigen presenting phenotype, including expression of human leukocyte antigens (HLA). They also express transporters of antigenic peptides (TAP1, TAP2), CD74, and tapasin required for proper antigen presentation, as well as co-stimulatory (B7, CD40, CD70) and cell adhesion molecules (ICAM-1 and LFA-3) [2].

Epstein Barr virus (EBV) is present in the tumor cells in approximately 30% of the cHL patients in Western Europe and plays a causal role in cHL pathogenesis [3]. The human leukocyte antigen (HLA) is a crucial component of the human immune system as it presents antigens to T cells. HLA class I restricted CD8+ cytotoxic T-cell (CTL) responses are known to target EBV infected cells through cell-mediated immunity [4]. HLA class I expression is retained in HRS cells in ~70% of the EBV+ cHL cases [5]. This is remarkable, since HLA class I restricted immune responses to EBV derived antigenic peptides should be detrimental to EBV+ HRS cells. Previous observations showed an enhanced HLA class I staining intensity in a proportion of the EBV+ cHL cases as compared to the surrounding lymphocytes [6,7]. In contrast, only ~15% of the EBV− cases retain HLA class I expression and positive cases showed a staining intensity similar to lymphocytes in the reactive infiltrate [5].

Promyelocytic leukemia protein (PML) and special AT-rich region binding protein 1 (SATB1) are two proteins that have been shown to regulate HLA class I expression. PML induces the expression of HLA class I heavy chains and microglobulin at the level of transcription, thereby restoring defective antigen presentation in lung cancer cell lines [13]. Down regulation of PML results in a reduced HLA-A (classical antigen...
presenting HLA class I) but an enhanced HLA-G (non-classical, non-antigen presenting HLA class I) expression in Jurkat cells [14]. SATB1 is highly abundant in T cells and acts as a global chromatin organizer. It is required for the assembly and maintenance of a higher-order chromatin loop architecture and it consequently regulates gene expression [15,16,17]. SATB1 partially resides within PML-NBs and has been shown to organize the HLA class I locus into distinct loops. Silencing of SATB1 in Jurkat cells results in an enhanced expression of HLA-A, HLA-G, HLA-H and HCG4P6 [14].

The mechanism of the altered HLA class I expression levels (stronger than normal or lost) observed in HRS cells in part of the EBV+ cHL cases is currently unknown. In this study, we investigated a possible association between PML-NBs, SATB1 and HLA class I expression in the HRS cells of EBV+ cHL.

**Materials and Methods**

**Patients**

We selected 54 primary EBV+ cHL cases and as a control 27 random primary EBV− cHL cases [18]. All cases were diagnosed between 1987 and 2009. The age at diagnosis ranged from 7 to 94 years. Tissues were retrieved from the tissue bank of the Pathology Department, University Medical Center Groningen. All diagnoses were established according to the classification guidelines of the World Health Organization [19]. The protocol was approved by the medical ethics board of the University Medical Center Groningen [18]. All protocols were carried out in accordance with the Declaration of Helsinki.

**Immunohistochemical Staining and Scoring of HLA Class I, PML-NBs and SATB1**

4-μm thick paraffin sections were deparaffinized by xylene and rehydrated through a graded ethanol series. Tissue sections were incubated with 0.3% hydrogen peroxide for 30 min to block endogenous peroxidase and heated in 1 mM Tris/EDTA solution (pH 9.0) for antigen retrieval. The slides were washed with PBS, and incubated with the primary antibodies against HLA class I, β2-microglobulin, PML and SATB1 (Table S1). The PML antibody detects all PML isoforms. The surrounding infiltrate served as a positive internal control, while PBS without primary antibody served as a negative control. Positive staining was visualized with 3,3-diaminobenzidine (DAB) after incubation with secondary and tertiary antibodies. Sections were counterstained with hematoxylin.

HLA class I heavy chain staining was scored for each case side by side with β2-microglobulin staining. The surrounding inflammatory cells were used as a reference for assessing the staining intensity. The staining intensity was scored as normal, i.e. similar to reactive lymphocytes, or strong, i.e. stronger than the reactive lymphocytes. Cases without membranous staining were scored as negative. For PML, we scored HRS cells based on the average number of PML-NBs in the nuclei of at least 20 HRS cells. The number of small discrete foci in the nucleus of HRS cells was counted. Initially, four scoring categories were used (average number of PML-NBs <6, 6–10, 11–15 or >15). Because the number of cases in the <6 and >15 categories were quite small, cases were grouped into two categories; with 10 or less PML-NBs per cell or >10 PML-NBs per cell (per 4 μm tissue section). In three random cases with <5 PML-NBs per nucleus and three random cases with >15 PML-NBs per nucleus we measured the nuclear surface area of 20 individual tumor cells in each case (120 tumor cells in total) by Aperio ImageScope software v11.1 after digitally capturing the slides (Aperio Scanscope). For SATB1, we scored the nuclear staining intensity and the percentage of SATB1 positive HRS cells. If there was no nuclear signal in tumor cells, we defined them as negative. If HRS cells stained weaker than the surrounding lymphocytes, we defined them as weakly positive. If HRS cells and surrounding cells had the same or a (slightly) stronger intensity as the surrounding infiltrating cells, we defined them as positive.

**Statistical Analysis**

Differences between HLA class I expression defined subgroups were evaluated by the Chi-square test or Fisher exact test. The Kruskal-Wallis test and post-hoc Dunn’s multiple comparison tests were used to test for statistically significant differences in age distribution and percentages of SATB1 positive HRS cells. For SATB1 staining intensity negative and weakly positive scores were grouped together. Linear regression analysis was used to evaluate whether the number of PML-NBs per nucleus was correlated to the nuclear surface area. Ordinal regression was used for multivariable analysis of factors contributing to HLA class I expression (factors with a p-value <0.1 in univariable analysis were included). P values less than 0.05 were considered to be significant. SPSS 20.0 was used for the analyses.

**Results**

**HLA Class I Expression and Patient Characteristics in Relation to EBV Status**

EBV+ tumor cell status was associated with mixed cellularity subtype and age (Table S2). Representative cases with negative, normal and strongly positive HLA class I staining in HRS cells are shown in Fig. 1A–C. HLA class I staining results were consistent with the β2-microglobulin staining results in all cases (data not shown). In the EBV− group, none of the cases showed a strong positive staining, 5 cases showed a normal staining intensity and 22 cases were negative for HLA class I. In the EBV+ group, 21 cases stained strongly positive, 19 showed a normal intensity and 14 cases were negative for HLA class I. This difference in HLA class I staining pattern was significantly different (P<0.0001; Table S2). Age, gender and clinical stage had no correlation with tumor cell HLA class I staining intensity in the EBV+ cHL patients. Significant differences were observed in the proportion of HLA class I negative, normal and strong positive cases between histological subtypes (P = 0.03, Table 1). All negative cases were of the nodular sclerosis subtype.

**PML Staining in Relation to HLA Class I Expression in EBV+ cHL**

The PML antibody stained PML-NBs as randomly distributed discrete nuclear dots in virtually all nuclei in the tissue. There was no diffuse nuclear PML staining. To correlate HLA class I to PML, a known regulator of HLA class I overexpression, the average number of PML-NBs per HRS cell was scored in EBV+ cHL (Table S3). Representative cases are shown in Fig. 1D and 1E. 38 cHL cases had an average of ≤10 PML-NBs per cell, while 16 cases showed an average of >10 PML-NBs per cell. The percentage of EBV+ cHL cases with >10 PML-NBs was significantly different between HLA class I groups, with the lowest frequency in HLA class I negative cases (1 out of 14, i.e. 7%), an intermediate frequency in HLA class I normal (3 out of 19, i.e. 16%) and the highest percentage in HLA class I strong positive (12 out of 21, i.e. 57%) cHL cases (p = 0.002, Fig. 2A). Post-hoc test indicated that the percentage of EBV+ cHL cases with >10 PML-NBs significantly differed between HLA class I negative and strong positive (P = 0.004) and between normal and strong positive cHL.
cases (P = 0.01). Strikingly, the 7 cases with the highest number of PML-NBs per HRS cell all had a strongly positive HLA class I staining. Thus, a high number of PML-NBs in HRS cells is correlated with enhanced HLA class I expression in EBV+ cHL.

To explore if the number of PML-NBs counted in a 4 μm tissue section is related to the size of the nucleus, we correlated the number of PML-NBs to the nuclear surface area in 20 individual tumor cells per case in 6 different cases (3 cases with low PML-NB numbers and 3 with high PML-NB numbers). The surface area of HRS cell nuclei in 4 μm tissue sections ranged from 66 to 412 μm² and the number of PML-NBs per nucleus ranged from 0 to 40. A weak negative correlation was observed with bigger nuclei having slightly less PML-NBs (p = 0.01, r² = 0.05, Figure 2B). Considering HRS cell nuclei as a sphere, we estimate that there are close to

Figure 1. Representative immunostaining results of HLA class I, SATB1 and PML-NBs.

(A) HLA class I negative case. There is no membranous staining between adjacent HRS cells, while membranes of surrounding cells were positive. (B) HLA class I positive case. Several adjacent HRS cells show positive membranous staining at the same intensity as the surrounding lymphocytes. (C) cHL case with a strongly positive HLA class I staining. Staining intensity of HRS cells is more pronounced than the intensity of the surrounding lymphocytes. (D) cHL case with an average of 4–10 PML-NBs per cell. One HRS cells with 4 tiny PML-NBs in the nucleus is shown. (E) cHL case with an average of >10 PML-NBs per cell. A representative HRS cell with more than 20 PML-NBs in the nucleus is shown. (F) cHL case without nuclear SATB1 staining in HRS cells. (G) Weakly positive nuclear SATB1 staining in HRS cells. (H) Positive nuclear SATB1 staining in HRS cells.

doi:10.1371/journal.pone.0072930.g001
zero to up to 170 PML-NBs in a complete HRS cell nucleus. In contrast, we saw on average only 3 to 5 PML-NBs per lymphocyte nucleus in the reactive infiltrate.

SATB1 Staining in Relation to HLA Class I Expression in EBV+ cHL

The percentage of SATB1 positive HRS cells varied from 0–100% in EBV+ cHL. Representative cHL cases with negative, weakly positive and positive SATB1 nuclear staining are shown in Fig. 1F–H. Weak SATB1 staining coincided with a highly variable percentage of SATB1 positive HRS cells, while positive SATB1 staining was related to higher percentages of SATB1 positive HRS cells (usually >50%). HLA class I results were compared to both the percentage and staining intensity of SATB1+ HRS cells. We observed a significant difference in the percentages of SATB1 positive cells between the HLA class I negative, normal and strongly positive groups (median 65%, 100% and 40%, p = 0.046, Fig. 2C) and post-hoc analysis showed that this was caused by the difference between normal and strong HLA class I staining. In the EBV+ group, 30 cases stained positive, whereas 24 cases were negative or showed a weak staining for SATB1. There was a significant difference of SATB1 staining intensity among HLA

Table 1. Statistical analysis of the correlation of clinicopathological characteristics, SATB1 and PML-NBs with HLA class I staining patterns in EBV+ cHL (n = 54).

|                  | HLA class I staining | Univariable analysis | Multivariable analysis |
|------------------|----------------------|----------------------|------------------------|
|                  | Negative | normal | strong | p value | p value* |
| **Age, median**  |          |        |        |          |          |
| median           | 22       | 49     | 56     |          |          |
| (min-max)        | (8–72)   | (8–88) | (7–94) |          |          |
| **Age, year**    |          |        |        |          |          |
| 0–14             | 3        | 33.3   | 3      | 33.3     |          |
| 15–44            | 7        | 41.2   | 5      | 29.4     | N.S.b    |          |
| 45–64            | 3        | 18.8   | 6      | 37.5     |          |          |
| > 65             | 1        | 8.3    | 5      | 41.7     |          |          |
| **Gender**       |          |        |        |          |          |
| M                | 6        | 18.2   | 12     | 36.4     |          |
| F                | 8        | 38.1   | 7      | 33.3     |          |
| **Clinical stage**|         |        |        |          |          |
| I                | 1        | 7.1    | 5      | 35.7     |          |
| II               | 7        | 41.2   | 5      | 29.4     | N.S.c    |          |
| III              | 6        | 46.2   | 3      | 23.1     |          |          |
| IV               | 0        | 0.0    | 1      | 100.0    |          |          |
| unknown          | 0        | 0.0    | 5      | 55.6     |          |
| **Histological subtype** | | | | | |
| Nodular Sclerosis| 14       | 40.0   | 8      | 22.9     | 13       | 37.1     | 0.026c  |
| Mixed Cellularity| 0       | 0.0    | 0      | 50.0     | 5        | 50.0     | 0.093   |
| LR/LD/NOS        | 0        | 0.0    | 6      | 66.7     | 3        | 33.3     |          |
| **Number of PML-NBs** | | | | | |
| 0–10 PML-NBs     | 13       | 34.2   | 16     | 42.1     | 9        | 23.7     | 0.002b  |
| > 10 PML-NBs     | 1        | 6.3    | 3      | 18.8     | 12       | 75.0     | 0.008   |
| **% of SATB1+ HRS cells** | | | | | |
| Median           | 65       | 100    | 40     |          |          |
| (min-max)        | (0–100)  | (0–100)| (0–100)|          |          |
| **SATB1 staining intensity** | | | | | |
| negative/weakly positive | 8 | 33.3 | 4 | 16.7 | 12 | 50.0 | 0.039b |
| positive         | 6        | 20.0   | 15     | 50.0     | 9        | 30.0     | 0.024   |

*Kruskal-Wallis test;  
Chi-square test;  
Fisher’s exact test;  
Ordinal regression analysis was left out of the model since it correlates to % of SATB1+ HRS cells. N.S., not significant. LR, lymphocyte rich. LD, lymphocyte deleted. NOS, not otherwise specified.  
doi:10.1371/journal.pone.0072930.t001
NBs significantly increased from HLA class I negative to normal and strong positive cHL cases (p = 0.002, Chi-square). Post-hoc test indicated that the percentage of PML-NBs is 57.9% in HLA class I negative, 75% in normal HLA class I cases and 75.6% in strong positive HLA class I cases. Therefore, there is a strong positive correlation between the number of PML-NBs and HLA class I expression (r = 0.6, p = 0.0002, Spearman's rank correlation).

There is a weak negative correlation between the number of PML-NBs and size of the tumor cell nucleus (r = -0.3, p = 0.01). (C) The percentage of SATB1 positive HRS cells in EBV+ cHL cases with negative, normal or strong HLA class I staining pattern differ significantly (p = 0.046, Kruskal-Wallis test). Dunn's multiple comparison test indicated a significant difference specifically between the HLA class I normal and strong staining groups. The median SATB1 percentage is indicated in each group. White symbols indicate the cases with no or weakly positive SATB1 staining, whereas black symbols indicate cases with positive SATB1 staining.

Discussion

The mechanism of enhanced expression of HLA class I in EBV+ cHL, as well as the down regulation of HLA class I in part of EBV+ and EBV− cHL is unclear. In this study, we showed that the enhanced HLA class I expression in EBV+ cHL is positively associated with the number of PML-NBs and inversely correlated with the nuclear staining intensity and the percentage of SATB1 positive tumor cells. There was no association between HLA class I negative eHL cases and either PML or SATB1, indicating that other mechanisms contribute to down regulation of HLA class I expression, e.g. loss of the HLA loci, aberrant transcription factor expression or epigenetic modifications.

In our case series, retention of HLA class I expression was observed in ~20% of EBV− and ~75% of EBV+ cHL. An even stronger than normal HLA class I expression was seen in half of the HLA class I positive EBV+ cHL cases. It is enigmatic how tumor cells benefit from retained or enhanced HLA class I expression in the face of anti-EBV immune responses. It is known that during primary lytic EBV infection of a naive B cell the HLA class I antigen presentation pathway is strongly inhibited by lytic EBV proteins (BNLF2a, BNLF5 and BILF1) [20,21,22]. However, when lytic infection switches to latent infection, the expression of HLA class I is restored. Moreover, it has been reported that LMP1 can enhance HLA class I expression levels to higher than normal [23]. In EBV+ cHL with high HLA class I expression there is an increased number of CTLs in the reactive infiltrate, suggesting that antigens are presented in the context of HLA class I. However, these CTLs are usually not in the close vicinity of HRS cells [6]. Previous studies from our group showed a strong association of two HLA-A types with EBV+ cHL [24,25]. HLA-A*01 is a risk type and has low affinity for LMP1 and LMP2 derived antigenic peptides, whereas HLA-A*02 is a protective type that has a relatively high affinity for LMP1 and LMP2 derived antigenic peptides [26,27]. Thus, lack of the HLA-A*02 type might explain why EBV+ HRS cells with HLA class I expression are not recognized and targeted by cytotoxic T cell mediated antitumor responses. In addition, HRS cells express immunosuppressive cytokines, such as TGF-β and IL-10 which can inhibit the cytotoxicity of these CTLs [28,29]. A possible advantage of HLA class I expression would be inhibition of natural killer (NK) cells. We have previously shown that HLA class I negative HRS cells commonly express the NK cell inhibiting cell surface protein HLA-G instead [5]. Whether EBV+ HRS cells would benefit from an increased HLA class I expression and what mechanism(s) would be involved remain open questions.

Enhanced HLA class I expression was correlated with an increased number of PML-NBs in EBV+ HRS cells. This increase was not due to an increase in size of HRS cell nuclei. In normal B and T lymphocytes the number of PML-NBs ranged from 3 to 5 per nucleus. We estimate that in HRS cells the number of PML-NBs ranges from close to zero to up to 170 PML-NBs per nucleus. The positive correlation of the number of PML-NBs with HLA class I expression is consistent with the results of a previous study showing that inhibition of PML-III and PML-V isoforms resulted in down regulation of the expression of a distinct set of HLA class I genes in Jurkat cells [14]. Overexpression of LMP1 in lung
epithelial cells induced PML protein expression and increased both the size and number of PML-NBs [30]. Considering that LMP1 can increase HLA class I in Burkitt lymphoma [23], we propose that this LMP1-mediated increase of HLA class I expression might be induced via induction of the number of PML-NBs.

We showed an inverse correlation between SATB1 and enhanced HLA class I expression in EBV+ cHL cases. This is consistent with previous findings in Jurkat cells showing that silencing of SATB1 increases HLA class I expression at the mRNA level from normal to strong [14]. Low SATB1 expression in EBV+ cHL was observed previously by microarray profiling of micro-dissected HRS cells [31]. Of note, SATB1 staining was more variable in HLA class I negative cases and not stronger in comparison to cases with normal expression. Therefore, there is no evidence in our study that increased SATB1 expression is associated with down regulation of HLA class I. We conclude that lack of SATB1 is only associated with stronger than normal HLA class I staining in EBV+ cHL.

Since SATB1 partially resides in PML-NBs we were interested to see whether these two factors have an independent effect on HLA class I expression. Multivariable analysis indicated that the number of PML-NBs is the most significant independent factor correlated with HLA class I expression in EBV+ cHL, while the percentage of SATB1+ tumor cells also had an independent effect. Although sometimes a subtle dot-like nuclear SATB1 staining could be observed, diffuse SATB1 nuclear staining prohibited scoring of SATB1 containing PML-NB. It is therefore unclear if the effect of SATB1 is caused by SATB1 located in PML-NBs, by diffuse SATB1 or by both.

In conclusion, strongly enhanced HLA class I expression in EBV+ cHL is positively correlated with the number of PML-NBs and negatively correlated with SATB1 at the protein level. SATB1 and PML may play an important role in up regulating HLA class I expression in EBV+ cHL.

Supporting Information

Table S1 Antibodies used for immunohistochemistry. (DOC)

Table S2 Patient characteristics, HLA class I, SATB1 and PML-NBs in EBV+ and EBV− cHL. (DOC)

Table S3 Clinical and pathologic characteristics and HLA class I, SATB1 and PML staining results for all cHL patients. (DOC)

Author Contributions

Conceived and designed the experiments: YL, AveB AD. Performed the experiments: YL RV BR. Analyzed the data: YL AD LV. Contributed reagents/materials/analysis tools: YL IN GvI. Wrote the paper: YL AveB AD. Retrieve clinical data: GvI.

References

1. Kuppers R, Braunninger A (2006) Reprogramming of the tumour B-cell phenotype in Hodgkin lymphoma. Trends Immunol 27: 203–205.

2. Delabie J, Chau WC, Weisenburger DD, De Wolf-Peeters C (1995) The antigen-presenting cell function of Reed-Sternberg cells. Leuk Lymphoma 18: 31–40.

3. Jarrett RF (2002) Viruses and Hodgkin’s lymphoma. Ann Oncol. 13 Suppl 1: 21–29.

4. Richardson AB, Moss DJ (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 13: 405–451.

5. Diepstra A, Poppema S, Boot M, Visser L, Noote IM, et al. (2008) HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma. Tissue Antigens 71: 219–226.

6. Oudejans JJ, Josa NM, Kummer JA, Horstman A, Vos W, et al. (1996) Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin’s disease. Blood 87: 3844–3851.

7. Huang X, van den Berg A, Gao Z, Visser L, Nolte IM, et al. (2010) Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients. PLoS One 5: e10865.

8. Lallemand-Breitenbach V, de H PML nuclear bodies. Cold Spring Harb Perspect Biol 2: a000661.

9. Defaire G, Bazett-Jones DP (2004) PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 965–977.

10. Condeelis W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, et al. (2006) PML-NBs, SATB1 and HLA class I in EBV+ cHL. This is a significant finding.

11. Cai S, Han HJ, Kohwi-Shigematsu T (2006) Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet 34: 42–51.

12. Cai S, Lee CC, Kohwi-Shigematsu T (2006) SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet 38: 1278–1288.

13. Chang SK, Park B, Shin J, Ahn JH, Kim IH, et al. (2002) Proto-oncogene PML enhances antigen-presenting cell function by increasing major histocompatibility complex class I expression on Reed-Sternberg cells. Leuk Lymphoma 43: 1–7.

14. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB (1997) Conserved latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA class I antigen expression. Eur J Immunol 27: 1374–1384.

15. Rowe M, Khamna R, Jacob CA, Argent V, Kelly A, et al. (1995) Restoration of endogenous antigen processing in Burkitt’s lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA class I antigen expression. Eur J Immunol 25: 3183–3184.

16. Hislop AD, Ressing ME, van Leeuwen D, Padney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863–1873.

17. Zuo J, Currin A, Griffin BD, Shannon-Loose C, Thomas WA, et al. (2009) The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5: e1000255.

18. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, et al. (2009) Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin’s lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 27: 3815–3821.

19. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, et al. (2005) PML-NBs, SATB1 and HLA class I in EBV+ cHL. This is a significant finding.

20. Zuo J, Thomas WA, van Leeuwen D, Middeldorp JM, Wiertz EJ, et al. (2008) The DNaSe of gamma-herpesviruses recognises reorganisation by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82: 2385–2393.

21. Hislop AD, Ressing ME, van Leeuwen D, Padney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863–1873.

22. Zuo J, Thomas WA, van Leeuwen D, Middeldorp JM, Wiertz EJ, et al. (2008) The DNaSe of gamma-herpesviruses recognises reorganisation by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82: 2385–2393.

23. Rowe M, Khamna R, Jacob CA, Argent V, Kelly A, et al. (1995) Restoration of endogenous antigen processing in Burkitt’s lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA class I antigen expression. Eur J Immunol 25: 1374–1384.

24. Niess M, Jarrett RF, Hepekerna B, Noote IM, Diepstra A, et al. (2007) HLA-A*0201 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110: 3310–3315.

25. Diepstra A, Niess M, Velleggs E, van Imhoff GW, Noote IM, et al. (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin’s lymphoma. Lancet 365: 2216–2224.

26. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325–3334.

27. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, et al. (2005) PML-NBs, SATB1 and HLA class I in EBV+ cHL. This is a significant finding.

28. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, et al. (2005) PML-NBs, SATB1 and HLA class I in EBV+ cHL. This is a significant finding.

29. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, et al. (1996) Frequent Epstein-Barr virus infection. Annu Rev Immunol. 15: 405–431.

30. Kuppers R, Brauninger A (2006) Reprogramming of the tumour B-cell phenotype in Hodgkin lymphoma. Trends Immunol 27: 203–205.

31. Jarrett RF (2002) Viruses and Hodgkin’s lymphoma. Ann Oncol. 13 Suppl 1: 21–29.
30. Sides MD, Block GJ, Shan R, Esteves KC, Lin Z, et al. (2011) Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology 416: 86–97.

31. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, et al. (2012) Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 120: 3530–3540.